
According to a new study that examined the real-world usage of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron), patients with wet age-related macular degeneration (AMD) required an equivalent number of injections over 6- and 12-month periods for both treatments.
 

.png)


